BioMaxima S.A.

BMX.WA

Medical - Diagnostics & Research · Healthcare

Price

10.08 PLN

+0.17 (+1.72%)

Market Cap

42.3M PLN

Exchange

Warsaw Stock Exchange

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 9, 2026 · filings through Mar 31, 2026

Share count falling — buybacks

−6.4% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 4.5M (2021) → 4.2M (2025)

BioMaxima S.A. is a Polish company that makes and sells products used in medical laboratories. Its core business includes diagnostic reagents, culture media, and laboratory consumables used by hospitals, clinics, and diagnostic labs to test patient samples and identify diseases. The company operates in the medical diagnostics industry and serves healthcare customers primarily in Poland and other Central and Eastern European markets.

BioMaxima earns revenue by selling its laboratory products directly to medical institutions and through distribution partners. It is a relatively small company, with a market capitalization near zero on the Warsaw Stock Exchange, and competes against larger international diagnostics firms that have greater scale and brand recognition. The company's thin gross margin of around 1.7% and negative operating margin highlight the main risk it faces: it struggles to cover its costs, meaning it must either grow sales significantly, cut expenses, or improve its product mix to reach sustainable profitability.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-7.6% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-44.1% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

23.9%ownership

Insiders own a meaningful stake in the company

Cash Runway

~0 months

$423,000 cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

BioMaxima S.A. has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

6.7%

Thin — 6.7% gross margin

Operating Margin

2.9%

Thin — 2.9% operating margin

ROCE

0.7%

Weak — 0.7% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+5.5%

Slow sales growth (+5.5% YoY)

EPS YoY

-116.3%

Earnings shrinking (-116.3% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

-0.9%

Burning cash (-0.9%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.28

Conservative — low debt load (0.28)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial